Cybin Inc Stock Price, News & Analysis

Cybin, a biopharmaceutical company, will have CEO Doug Drysdale presenting at the KCSA Psychedelics Virtual Investor Conference on April 28, 2022, at 11:00 a.m. ET. This live online event allows investors to interact and ask questions directly. Cybin focuses on developing therapeutics using psychedelics to address mental health issues through innovative drug discovery platforms and treatment regimens. Investors can register for the event via the provided link and access the archived webcast later.

Cybin Inc. has partnered with Clinilabs Drug Development Corporation to conduct a Phase 1/2a clinical trial for CYB003, a proprietary deuterated psilocybin analog, aimed at treating major depressive disorder (MDD). This marks the first evaluation of a psilocybin analog in clinical trials for MDD. The partnership is expected to expedite the regulatory pathway for CYB003, which has shown advantages in preclinical studies, including better tolerability and faster action compared to classic psilocybin. An IND filing with the FDA is anticipated in Q2 2022.

Cybin Inc. announced promising preclinical results for its proprietary drug CYB004, delivered via inhalation. The study indicates that inhaled CYB004 has a rapid onset, longer action duration, and over 40% improved bioavailability compared to inhaled DMT. These findings may position inhalation as a viable method for delivering therapeutic psychedelics. Cybin aims to address the limitations associated with IV administration of DMT in treating anxiety disorders. The company plans to file for a pilot study by Q2 2022 and commence it in Q3 2022.

Cybin Inc. (AMEX:CYBN) has announced the publication of an international patent application by the World Intellectual Property Organization (WIPO) covering inhalation delivery methods for various psychedelic molecules. This PCT application strengthens Cybin’s intellectual property position, particularly for its CYB004 pipeline program utilizing deuterated DMT via inhalation. The patent allows the company to pursue applications for multiple inhaled forms of psychedelics, aligning with its strategy of creating improved treatment options for mental health disorders.

Cybin announces participation in the Benzinga Psychedelics Capital Conference on April 19, 2022. CEO Doug Drysdale will engage in a fireside chat at 1:10 p.m. ET and a panel discussion at 3:10 p.m. ET focused on catalysts in the psychedelics industry. The event will be streamed live, and recordings will be available on the company’s investor relations website. Founded in 2019, Cybin is a biopharmaceutical firm dedicated to creating effective therapeutics for mental health issues, operating in multiple countries including Canada and the U.S.

Cybin Inc. has announced that its subsidiary, Adelia Therapeutics, has met a milestone outlined in a previous transaction agreement. This achievement will lead to the issuance of 22,428.3 Class B common shares, representing approximately $228,769 to Adelia shareholders. The shares can be exchanged for Cybin's common shares at a specific ratio. CEO Doug Drysdale expressed satisfaction with the progress, indicating it supports clinical development for psychedelic-based therapies. The company aims to advance innovative drug delivery systems for mental health disorders.

Cybin Inc. (AMEX:CYBN) has initiated a feasibility study utilizing Kernel's Flow technology to objectively measure the effects of ketamine on brain activity during psychedelic experiences. This study is poised to gather quantitative data, a significant advancement compared to previous subjective reporting methods. Authorized by the FDA in October 2021, the study will involve participants receiving either low-dose ketamine or a placebo. Cybin retains exclusive rights to innovations resulting from the study, reinforcing its commitment to advancing psychedelic therapies.

Cybin Inc. has completed in vivo preclinical studies of its deuterated psilocybin analog CYB003 for treating major depressive disorder (MDD). The studies indicate CYB003 is well-tolerated and shows promising pharmacological properties, including a 50% reduction in dosage variability and faster onset compared to classic psilocybin. The Company plans to submit an IND to the FDA in Q2 2022 and initiate Phase 1/2a trials by mid-2022, aiming to advance CYB003 as a potential treatment for MDD and alcohol use disorder.

Cybin Inc. announced milestones achieved by its subsidiary, Adelia Therapeutics, in accordance with a Transaction Agreement dated December 4, 2020. As a result, 90,546 Class B common shares will be issued to Adelia shareholders, fulfilling an obligation of approximately $904,916.81. Each Class B Share is exchangeable for 10 Cybin Shares, starting December 14, 2021, with specific percentages unlockable in subsequent years. This transaction reflects Cybin's commitment to developing psychedelics for therapeutic use.